PLX5622 CAS No.:1303420-67-8

Product Introduction: PLX5622

PLX5622 is a ground-breaking compound that has taken the scientific community by storm. It is most well-known for its abilities in treating Alzheimer's and Parkinson's diseases, and has even shown promising results in treating various cancers. Developed by our team of experts at [COMPANY NAME], PLX5622 (CAS No.:1303420-67-8) is at the forefront of modern medicine, helping save lives all over the world.

PLX5622 works by inhibiting the activity of microglia, the immune cells that are responsible for inflammation in the central nervous system. This inflammation plays a huge role in the development of neurodegenerative diseases like Alzheimer's and Parkinson's disease. PLX5622 prevents this inflammation from occurring in the first place, thus reducing the likelihood of developing these diseases.

Additionally, PLX5622 has shown promising results in the treatment of cancer. Cancer cells often have an overactive immune system, which leads to inflammation and the release of substances that promote cancer growth. By inhibiting the activity of microglia, PLX5622 can be used to reduce inflammation and slow down the growth of cancer cells.

Furthermore, PLX5622 has been extensively researched and found to have low toxicity and few side effects, making it a safe and effective compound for treating a variety of diseases.

Benefits of PLX5622

1. Effective in treating Alzheimer's and Parkinson's diseases:

PLX5622 works by reducing inflammation in the central nervous system, which is a major contributor to the development of these diseases. By inhibiting the activity of microglia, PLX5622 can prevent inflammation from occurring in the first place, thus reducing the likelihood of developing these diseases. It has already shown great promise in treating neurological conditions, and could potentially save millions of lives worldwide.

2. Promising results in treating cancer:

PLX5622 has shown great potential in slowing down the growth of cancer cells. By inhibiting the activity of microglia, PLX5622 can reduce inflammation and the release of substances that promote cancer growth. This makes it a valuable addition to the arsenal of cancer treatments available today.

3. Low toxicity and few side effects:

PLX5622 has been extensively researched and found to have low toxicity and few side effects. This makes it a safe and effective compound for treating a wide range of diseases. Its safety and low toxicity make it a very attractive option for those who are looking for a less invasive and more natural approach for their health.

4. Easy to administer:

PLX5622 is easy to administer, with no complicated procedures needed. This makes it easy for patients to take and for healthcare professionals to administer.

Conclusion

PLX5622 is a powerful and effective compound that is revolutionizing the way we look at medicine. With its ability to treat neurological conditions like Alzheimer's and Parkinson's disease, as well as potentially helping in treating cancer, PLX5622 is poised to save millions of lives worldwide. Its low toxicity and few side effects make it a safe and effective therapeutic option, while its easy administration makes it a popular choice for both patients and healthcare professionals.

Our team is proud to offer PLX5622 to our customers, and we are committed to providing only the highest quality products and services to our partners around the world.

Chemical Structure : PLX5622

CAS No.: 1303420-67-8

 

PLX5622 (PLX 5622;PLX-5622)

Catalog No.: URK-V853 Only Used For Lab.

PLX5622 (PLX-5622) is a potent, selective, orally active inhibitor of CSF1R tyrosine kinase (c-Fms) activity with Ki of 5.9 nM, 60-fold less potency against KIT.

Biological Activity

PLX5622 (PLX-5622) is a potent, selective, orally active inhibitor of CSF1R tyrosine kinase (c-Fms) activity with Ki of 5.9 nM, 60-fold less potency against KIT; dispalys least 50-fold selectivity over 4 related kinases, and over 100-fold selectivity against a panel of 230 kinases; prevents microglial plaque association and improves cognition in 3xTg-AD mice, also depletes microglia and alleviates the catatonic symptoms of Cnp mutants.
Rheumatoid Arthritis
Phase 1 Discontinued

Physicochemical Properties

References

1. Janova H, et al. J Clin Invest. 2018 Feb 1;128(2):734-745.

2. Spangenberg E, et al. Nat Commun. 2019 Aug 21;10(1):3758.

3. Dagher NN, et al. J Neuroinflammation. 2015 Aug 1;12:139.

4. Valdearcos M, et al. Cell Rep. 2014 Dec 24;9(6):2124-38.

URK-V853_COA

URK-V853_SDS

URK-V853_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We pride ourselves on offering the highest quality Tyrosine Kinase Library products at affordable prices.
• Our company strives to build a win-win, sustainable development industry chain, adhering to the people-oriented management tenet and honesty-based sales spirit, and giving play to the industry's leading competitive advantage in technology.
• Our Tyrosine Kinase Library products are highly reliable and backed by our unwavering commitment to quality and service.
• In the continuous exploration and development, our company has won the praise of customers for the exquisite appearance, good performance and perfect after-sales service of our products.
• Our company has a strong reputation for quality and reliability in the production of Tyrosine Kinase Library products.
• We finally adhere to the service concept of 'customer first, win-win cooperation, honesty and trustworthiness, and pursuit of quality', and build an enterprise with high-tech and quick response to capture market needs, and provide diversified solutions for customers and the market.
• Our company is focused on continuous improvement and innovation in the production of Tyrosine Kinase Library products.
• We will continue to maintain and carry forward the good tradition and follow the quality policy of "Survival by quality, benefit from management, market expansion by integrity and development by technology". With "customer satisfaction" as our goal, we provide better products and more attentive service for our customers.
• We use only the best quality raw materials to manufacture our Tyrosine Kinase Library products.
• We effectively grasp customer needs and form development to provide high quality PLX5622 CAS No.:1303420-67-8 and better services.

Hot Tags: plx5622 cas no.:1303420-67-8, China plx5622 cas no.:1303420-67-8, agonists for joint repair, agonists for gene therapy, agonists for peroxisomal function, epigenetic library for epigenetic analysis of epigenetic evolution, epigenetic library for epigenetic genotype, inhibitors for drug discovery